Akero Therapeutics Stock Target Price and Analyst Consensus
| AKRO Stock | USD 43.70 0.17 0.39% |
The current analyst and expert consensus on Akero Therapeutics is Strong Buy, with 7 strong buy opinions. The current projected Akero Therapeutics target price consensus is 48.27 with 11 analyst opinions. Check out Macroaxis Advice on Akero Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.The most common way Akero Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Akero Therapeutics executives and customers to further validate their buy or sell advice. Akero Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Akero Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 13.0447.
Lowest Forecast 43.93 | Highest Forecast 53.58 | Target Price 48.27 |
Akero |
It's important to approach Akero Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Akero Therapeutics Target Price Consensus
Akero target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Akero Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Akero analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Akero stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Akero Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAkero Therapeutics Target Price Projection
Akero Therapeutics' current and average target prices are 43.70 and 48.27, respectively. The current price of Akero Therapeutics is the price at which Akero Therapeutics is currently trading. On the other hand, Akero Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Akero Therapeutics Market Quote on 19th of March 2025
Target Price
Analyst Consensus On Akero Therapeutics Target Price
Akero Therapeutics Analyst Ratings
Akero Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Akero Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Akero Therapeutics' financials, market performance, and future outlook by experienced professionals. Akero Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Akero Therapeutics price targets
Akero Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Akero Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Akero Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Akero Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Akero Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Akero Therapeutics is a key component of Akero Therapeutics valuation and have some predictive power on the future returns of a Akero Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Business Services Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Macroaxis Index Invested few shares | |
 | Automobiles and Trucks Invested over 60 shares | |
 | Cash Cows Invested few shares | |
 | SRI Sustainable Growth Invested over 40 shares | |
 | Apparel Invested over 40 shares | |
 | Casinos Sold over 90 shares | |
 | Utilities Invested over 90 shares | |
Check out Macroaxis Advice on Akero Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.